Literature DB >> 12879460

Chronic myelogenous leukemia: a review and update of therapeutic strategies.

Guillermo Garcia-Manero1, Stefan Faderl, Susan O'Brien, Jorge Cortes, Moshe Talpaz, Hagop M Kantarjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12879460     DOI： 10.1002/cncr.11520

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  19 in total

1.  Massive subcutaneous bleeding as a first manifestation of chronic myeloid leukemia in chronic phase.

Authors:  Antica Duletic Nacinovic; Bojan Miletic; Dubravka Topljak-Polic; Sanja Balen; Davor Stimac
Journal:  Wien Klin Wochenschr       Date:  2004-08-31       Impact factor: 1.704

2.  PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Authors:  Nicholas C Wolff; Darren R Veach; William P Tong; William G Bornmann; Bayard Clarkson; Robert L Ilaria
Journal:  Blood       Date:  2005-01-18       Impact factor: 22.113

3.  Pathways to Genome-targeted Therapies in Serous Ovarian Cancer.

Authors:  Joshua Axelrod; Joe Delaney
Journal:  J Nat Sci       Date:  2017-07

4.  Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Authors:  Naoto Takahashi; Tetsuzo Tauchi; Kunio Kitamura; Koichi Miyamura; Yoshio Saburi; Yoshihiro Hatta; Yasuhiko Miyata; Shinichi Kobayashi; Kensuke Usuki; Itaru Matsumura; Yosuke Minami; Noriko Usui; Tetsuya Fukuda; Satoru Takada; Maho Ishikawa; Katsumichi Fujimaki; Hiroshi Gomyo; Osamu Sasaki; Kohshi Ohishi; Takaaki Miyake; Kiyotoshi Imai; Hitoshi Suzushima; Hideki Mitsui; Kazuto Togitani; Toru Kiguchi; Yoshiko Atsuta; Shigeki Ohtake; Kazunori Ohnishi; Yukio Kobayashi; Hitoshi Kiyoi; Yasushi Miyazaki; Tomoki Naoe
Journal:  Int J Hematol       Date:  2017-09-19       Impact factor: 2.490

Review 5.  Treatment of chronic myeloid leukemia with imatinib mesylate.

Authors:  Ryuzo Ohno
Journal:  Int J Clin Oncol       Date:  2006-06       Impact factor: 3.402

6.  Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.

Authors:  Xin-xin Xiong; Ju-mei Liu; Xin-yao Qiu; Feng Pan; Shang-bin Yu; Xiao-qian Chen
Journal:  Acta Pharmacol Sin       Date:  2015-01-26       Impact factor: 6.150

7.  Cytotoxic activities of new iron(III) and nickel(II) chelates of some S-methyl-thiosemicarbazones on K562 and ECV304 cells.

Authors:  Belkis Atasever; Bahri Ulküseven; Tülay Bal-Demirci; Serap Erdem-Kuruca; Zeynep Solakoğlu
Journal:  Invest New Drugs       Date:  2009-06-04       Impact factor: 3.850

Review 8.  Management options for refractory chronic myeloid leukemia: considerations for the elderly.

Authors:  Massimo Breccia; Giuliana Alimena
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

9.  Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases.

Authors:  Shardul Paricharak; Tom Klenka; Martin Augustin; Umesh A Patel; Andreas Bender
Journal:  J Cheminform       Date:  2013-12-13       Impact factor: 5.514

10.  Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Authors:  Musa Yilmaz; Amit Lahoti; Susan O'Brien; Graciela M Nogueras-González; Jan Burger; Alessandra Ferrajoli; Gautam Borthakur; Farhad Ravandi; Sherry Pierce; Elias Jabbour; Hagop Kantarjian; Jorge E Cortes
Journal:  Cancer       Date:  2015-07-28       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.